Cardiac Resynchronization Therapy Cuts Heart Failure Mortality by 34 Percent
A JAMA review synthesizes evidence showing CRT significantly reduces mortality and hospitalizations in heart failure patients with electrical dyssynchrony.
Summary
Heart failure affects over 64 million people worldwide, and a significant subset develop electrical dyssynchrony — a mismatch in the timing of heart chamber contractions — that accelerates disease progression. This JAMA review examines cardiac resynchronization therapy (CRT), which uses specialized pacing devices to restore coordinated ventricular contraction. Evidence from large meta-analyses shows biventricular pacing reduces all-cause mortality by 34% compared to medical therapy alone. A newer approach, conduction system pacing, uses a single lead to stimulate the heart's natural electrical pathway and shows promising improvements in heart function and fewer hospitalizations. The review also highlights that delayed referral for these devices worsens outcomes, underscoring the need for timely identification and treatment of eligible patients.
Detailed Summary
Heart failure is a global epidemic affecting more than 64 million people, carrying a one-year mortality rate exceeding 23% following acute episodes in North America and Europe. A critical but underappreciated driver of disease progression is cardiac dyssynchrony — abnormal electrical conduction that causes the heart's chambers to contract out of sync. This review in JAMA synthesizes the current evidence base for cardiac resynchronization therapy (CRT) as a treatment for this condition.
Electrical dyssynchrony, most commonly manifesting as left bundle-branch block, affects 20–30% of patients with reduced left ventricular ejection fraction (LVEF). CRT encompasses two device-based strategies: biventricular pacing, which uses two leads to simultaneously stimulate both ventricles, and the newer conduction system pacing, which uses a single lead targeting the His bundle or left bundle branch to engage the heart's intrinsic conduction pathway.
The mortality evidence for biventricular pacing is compelling. A patient-level meta-analysis of five randomized trials involving 3,872 patients found a 34% reduction in all-cause mortality compared to medical therapy or ICD alone over nearly two years of follow-up. Conduction system pacing, while studied in smaller trials, showed superior improvement in LVEF and was associated with a 33% reduction in heart failure hospitalizations in an observational study of 1,778 patients. It also significantly reduced pacing-induced cardiomyopathy in patients requiring chronic pacing for atrioventricular block.
The review emphasizes that delayed referral for CRT is independently associated with worse outcomes, making timely identification of eligible patients a clinical priority. Guidelines recommend CRT for symptomatic HF patients on optimal medical therapy with LVEF ≤35% and left bundle-branch block.
While the evidence is robust for biventricular pacing, conduction system pacing data largely come from small trials and observational studies. Larger randomized trials are needed to confirm its superiority and define optimal patient selection.
Key Findings
- Biventricular pacing reduced all-cause mortality by 34% vs. medical therapy or ICD in a meta-analysis of 3,872 patients.
- Conduction system pacing improved LVEF by an additional 2.06% compared to biventricular pacing in a meta-analysis.
- Conduction system pacing cut heart failure hospitalizations by 33% vs. biventricular pacing in an observational study.
- Pacing-induced cardiomyopathy occurred in only 6% with conduction system pacing vs. 15% with right ventricular pacing.
- Delayed referral for CRT is independently associated with worse clinical outcomes in eligible patients.
Methodology
This is a narrative review published in JAMA synthesizing evidence from multiple sources including a patient-level meta-analysis of 5 RCTs (N=3,872), a meta-analysis of 7 small RCTs (N=408), a large observational study (N=1,778), and a single trial of 249 patients. The review covers both biventricular and conduction system pacing approaches across heart failure and bradycardia indications.
Study Limitations
The summary is based on the abstract only, as the full text was not accessible. Evidence for conduction system pacing relies heavily on small randomized trials and observational data, limiting definitive conclusions about its superiority over biventricular pacing. Larger, adequately powered randomized controlled trials comparing the two CRT modalities head-to-head are still needed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.